Awardee OrganizationUNIV OF NORTH CAROLINA CHAPEL HILL
Description
Abstract Text
One of the recently characterized Ro/SS-A (Ro) genes encodes a 52 kD
autoantigen that contains a zinc finger motif. The 52 kD Ro protein's
novel zinc finger motif has significant homologies with sequences found in
a number of DNA binding proteins. Zinc finger motifs have been described
in numerous DNA binding proteins, most of which have gene regulatory
functions.
To test the hypothesis that 52 kD Ro is a DNA binding protein, DNA
cellulose binding experiments were conducted. The results reveal that the
native and recombinant 52 kD Ro proteins bind DNA with high affinity and
in a zinc-dependent fashion. Whole genome polymerase chain reaction
methods were utilized to isolate human genomic DNA fragments that are
specifically bound by the 52 kD Ro protein. Naturally occurring Ro
autoantibodies prevent 52 kD Ro protein from binding DNA.
Studies are now proposed to characterize the DNA sequences that are bound
by the 52 kD Ro protein, and to authenticate the DNA binding sites by
using synthetic oligonucleotides in competitive binding experiments and
gel shift assays. The target sequence(s) will be compared to previously
characterized regulatory elements. Genes that contain these target
sequences will be identified by searching the DNA databases or if
necessary by screening a human genomic DNA library. Gene fragments that
contain the target sequence will be subjected to competitive binding
assays, gel shift assays and (or) DNase protection assays to confirm that
the 52 kD Ro protein binds to them. Transfection studies will investigate
the cellular effects caused by over-expressing the 52 kD Ro protein in
human cells.
These studies will: 1) determine DNA sequence(s) bound by the 52 kD Ro
antigen; 2) identify genes whose expression is regulated by the 52 kD Ro
antigen; and 3) elucidate the cellular function of the 52 kD protein. The
outcome of these studies should have a significant impact on our
understanding of the role that this autoantigen plays in the Ro
autoantibody-associated immune disorders and thus may expedite the
development of better strategies for treating those afflicted.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
608195277
UEI
D3LHU66KBLD5
Project Start Date
01-August-1995
Project End Date
31-July-1998
Budget Start Date
01-August-1995
Budget End Date
31-July-1996
Project Funding Information for 1995
Total Funding
$107,858
Direct Costs
$74,642
Indirect Costs
$33,216
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$107,858
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AR043167-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AR043167-01A1
Patents
No Patents information available for 1R01AR043167-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AR043167-01A1
Clinical Studies
No Clinical Studies information available for 1R01AR043167-01A1
News and More
Related News Releases
No news release information available for 1R01AR043167-01A1
History
No Historical information available for 1R01AR043167-01A1
Similar Projects
No Similar Projects information available for 1R01AR043167-01A1